{"id":41398,"date":"2025-09-15T15:56:10","date_gmt":"2025-09-15T07:56:10","guid":{"rendered":"https:\/\/flcube.com\/?p=41398"},"modified":"2025-09-15T15:56:11","modified_gmt":"2025-09-15T07:56:11","slug":"biokin-pharma-secures-breakthrough-therapy-designation-for-izalontamab-with-bms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41398","title":{"rendered":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS"},"content":{"rendered":"\n<p>China\u2011based <strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced today that its bispecific antibody\u2011drug conjugate (ADC), <strong>izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1)<\/strong>, has received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).<br>The designation targets <strong>platinum\u2011resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer<\/strong>, positioning izalontamab as a first\u2011in\u2011class therapy in a high\u2011unmet\u2011need patient population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-co-development-and-global-rights\">Co\u2011Development and Global Rights<\/h2>\n\n\n\n<p>izalontamab is an <strong>EGFR\u202f\u00d7\u202fHER3 bispecific ADC<\/strong> and the only candidate of its kind in Phase\u202f3 clinical development worldwide.<br>In <strong>December\u202f2023<\/strong>, Biokin Pharma signed a licensing and collaboration agreement with <strong>Bristol\u2011Myers Squibb (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)<\/strong>. Under the deal, BMS receives <strong>global development and commercialization rights<\/strong> outside mainland China, while Biokin retains all rights within China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-pipeline-and-market-impact\">Clinical Pipeline and Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Trials:<\/strong> Over 40 active trials across China and the United States span multiple tumor types.<\/li>\n\n\n\n<li><strong>Phase\u202f3 Status:<\/strong> The BTD is expected to accelerate the pivotal study schedule, potentially shortening the time to regulatory submission.<\/li>\n\n\n\n<li><strong>Strategic Advantage:<\/strong> The partnership combines Biokin\u2019s domestic market expertise with BMS\u2019s global commercialization capabilities, creating a unique pathway for a novel ADC in the oncology landscape.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h2>\n\n\n\n<p>The BTD designation is a significant milestone for both companies, underscoring the therapeutic promise of bispecific ADCs in gynecologic oncology. If the Phase\u202f3 program meets its endpoints, izalontamab could become a new standard of care for patients with platinum\u2011resistant disease, driving substantial growth for Biokin in China and for BMS in international markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688506_20250911_XYZL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20250911_XYZL.\"><\/object><a id=\"wp-block-file--media-fae8da65-eb8a-4f30-b369-aa3604969930\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688506_20250911_XYZL.pdf\">688506_20250911_XYZL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688506_20250911_XYZL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fae8da65-eb8a-4f30-b369-aa3604969930\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41402,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,429,34,428,16,849,857],"class_list":["post-41398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-bms","tag-breakthrough-therapy","tag-bristol-myers-squibb","tag-cancer","tag-nyse-bmy","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41398\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41398\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T07:56:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-15T07:56:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS\",\"datePublished\":\"2025-09-15T07:56:10+00:00\",\"dateModified\":\"2025-09-15T07:56:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1505.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"BMS\",\"Breakthrough therapy\",\"Bristol-Myers Squibb\",\"Cancer\",\"NYSE: BMY\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41398#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41398\",\"name\":\"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1505.webp\",\"datePublished\":\"2025-09-15T07:56:10+00:00\",\"dateModified\":\"2025-09-15T07:56:11+00:00\",\"description\":\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41398\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41398#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41398","og_locale":"en_US","og_type":"article","og_title":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS","og_description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","og_url":"https:\/\/flcube.com\/?p=41398","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T07:56:10+00:00","article_modified_time":"2025-09-15T07:56:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41398#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41398"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS","datePublished":"2025-09-15T07:56:10+00:00","dateModified":"2025-09-15T07:56:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41398"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41398#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","BMS","Breakthrough therapy","Bristol-Myers Squibb","Cancer","NYSE: BMY","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41398#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41398","url":"https:\/\/flcube.com\/?p=41398","name":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41398#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41398#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","datePublished":"2025-09-15T07:56:10+00:00","dateModified":"2025-09-15T07:56:11+00:00","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code: BL\u2011B01D1), has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41398#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41398"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41398#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","width":1080,"height":608,"caption":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41398#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biokin\u202fPharma Secures Breakthrough Therapy Designation for izalontamab with BMS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41398"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41398\/revisions"}],"predecessor-version":[{"id":41403,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41398\/revisions\/41403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41402"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}